体内
多发性骨髓瘤
白细胞介素2
人源化抗体
药理学
受体
医学
抗体
白细胞介素-6受体
白细胞介素6
白细胞介素
免疫学
细胞因子
内分泌学
内科学
生物
单克隆抗体
生物技术
作者
Hirofumi Shinkura,Ikuo Imazeki,Masaki Yamazaki,Yasuhiro Oda,Masao Kotoh,Makoto Mihara
出处
期刊:PubMed
日期:1998-06-06
卷期号:18 (2A): 1217-21
被引量:11
摘要
A humanized antibody to human interleukin-6 (IL-6) receptor, MRA, which was constructed by grafting the complementary determining regions, is expected to be useful as a therapeutic agent for IL-6-related diseases, especially multiple myeloma. We examined the ability of MRA to block the in vivo function of IL-6 and its serum concentration profile in primates. Cynomolgus monkeys were intravenously administered with MRA at doses of 0 (vehicle) or 5 mg/kg, then subcutaneously injected with human IL-6 at a dose of 5 micrograms/kg, once a day for 7 days. The injections of IL-6 increased blood platelet counts two-fold and elevated serum C-reactive protein levels to 0.15 to 0.17 mg/ml. These IL-6-induced typical responses were completely inhibited by single pretreatment with MRA. Serum concentrations of MRA were maintained for a long period; some even at one week after administration, were regarded as having sufficient levels to inhibit the myeloma cell growth. These findings suggest that MRA may be effective in the treatment of IL-6-related diseases.
科研通智能强力驱动
Strongly Powered by AbleSci AI